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Abstract
Introduction: The high prevalence of chronic hepatitis C (CHC) and its consequent cirrhosis has been associated with bone
fragility. Whether CHC may cause bone and mineral abnormalities in the absence of hepatocellular dysfunction is still
unknown. In this study we aimed to determine the prevalence of osteoporotic vertebral fractures and low BMD
measurements in men with non-cirrhotic CHC. Risk factors for low BMD and fractures were also investigated.
Methods: Morphometric vertebral fractures and BMD measurements were performed in 60 non-cirrhotic untreated men
with CHC and 59 healthy controls, matched for age and gender, weight and current smoking. Serum CTx, calcium,
phosphate, intact PTH, alkaline phosphatase and vitamin D (25OHD) concentrations were measured in all participants.
Clinical risk factors for low BMD and fractures were evaluated by a structured questionnaire as well as details regarding HCV
infection.
Results: Trochanter and total femur BMD were significantly lower in CHC patients as compared to healthy men (p = 0.04). In
men 50 years and older, the prevalence of osteoporosis was significantly higher among CHC patients (p = 0.01). Lower levels
of physical activities and more often report of prolonged immobilization were observed among CHC patients (p,0.05).
Liver inflammation and fibrosis, viral load and genotype did not correlate with BMD measurements. Bone markers and
25OHD concentrations were similar in both groups. Only a few vertebral fractures were observed.
Conclusions: Our results demonstrate that non-cirrhotic untreated CHC patients have lower BMD at the femur as compared
to healthy men in spite of the absence of significant bone and mineral abnormalities.
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Introduction
The World Health Organization (WHO) has estimated that
about 3% of the world population has positive serology for
hepatitis C virus (HCV) (approximately 170 million of people) [1].
Bone diseases are common complications of chronic hepatitis C
(CHC), mainly related to the associated cirrhosis. Among the bone
abnormalities reported, hepatitis C-associated osteosclerosis
(HCAO) is a rare acquired condition characterized by generalized
increase in bone mineral density (BMD), bone pain, elevated
serum alkaline phosphatase, generalized cortical thickening and
increased uptake on bone scan [2–4].
Bone loss has been described as a complication of viral cirrhosis
[5–9] and its prevalence increases in more severe cases [5–7].
Higher levels of serum soluble tumor necrosis factor (TNF)
receptor 55 [8] and lower levels of 25-hydroxy vitamin D
(25OHD) [5,7,8], testosterone [5,7] and IGF-I in more advanced
Child-Pugh stages [7,8] may all contribute to the lower BMD
measurements observed among patients with more severe disease.
Bone disorders have been clearly associated with the presence of
cirrhosis per se, regardless of its cause. In patients with CHC and
other viral hepatitis, their treatment may also be considered as a
confounder when evaluating bone complications. It has been
reported that the combination therapy for patients with CHC
consisting of interferon-a (INF-a) plus ribavirin resulted in bone
loss after 12 months [10]. Increased BMD as well as no change
have also been reported after treatment with INF-a in patients
with CHC [11,12].
On the other hand, BMD and bone metabolism abnormalities
in non-cirrhotic hepatitis C patients have not been well
investigated. Whether chronic HCV infection in the absence of
cirrhosis or viral treatment is a risk factor for the development of
bone disease has long been controversial.
Only a few studies have evaluated bone status in CHC patients
[13–15]. Some methodological questions associated to current
treatment in some of the patients and the absence of a healthy
control group for comparison has limited the results of those
studies. Considering the lack of solid evidence for an effect of
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chronic HCV infection on bone status, in the present study we
evaluated BMD measurements, bone and mineral metabolism and
the prevalence of vertebral osteoporotic fractures in non-cirrhotic
men with untreated CHC infection as compared to healthy age-
matched controls.
Materials and Methods
Ethics Statement
Ethical approval was obtained from the Universidade Federal
de Sa˜o Paulo’s ethics committee and all participants gave written
informed consent prior to their inclusion in this study.
Patients
Sixty men (mean age 41.5610.9 years old) with CHC infection
consecutively seen at the UNIFESP’s outpatients clinics and fifty-
nine healthy men (mean age 41.7610.8 years) were invited to
participate in the present study. Anti-HCV/HCV RNA-positive
patients (N=60) had been followed for at least 6 months with
persistently positive serology for HCV and negative serological
markers for hepatitis B and human immunodeficiency virus (HIV).
Healthy men (N= 59) were selected from blood donators
registered at our center.
CHC patients with any clinical, laboratorial or histological
cirrhosis were excluded, as well as those previously or currently
treated with interferon/ribavirin therapy. Other exclusion criteria
for both CHC patients and healthy controls included alcoholism
(defined as more than 2 drinks per day) [17], diseases or use of
drugs that interfere with bone metabolism (corticosteroids,
levothyroxine, calcium and vitamin D supplements, diuretics,
bisphosphonates, anabolic agents), diabetes mellitus, lung diseases
and autoimmune hepatitis.
Body weight was measured (after removal of shoes and heavy
outer clothing) using a balance beam scale. Height was measured
(after removal of shoes) using a Filizola stadiometer. Height and
weight were used to calculate the body mass index (BMI; kg/m2).
Data about smoking and drinking habits, physical activity,
prolonged immobilization, familial history of osteoporosis and
hip fracture were obtained using a structured questionnaire based
on the European Vertebral Osteoporosis Study (EVOS) [18,19]
and validated for our language and culture [20–22]. Patients and
controls were matched for age, gender, weight, current smoking
and alcohol use.
Bone density measurements
BMD measurements were performed in all subjects at the
lumbar spine (L1-L4) and proximal femur (neck, trochanter and
total hip) using dual X-ray absorptiometry (DXA) (DPX MD+,
GE-Lunar, Madison, WI, USA). The coefficient of variation for
BMD measurements was 1.5% and 2% at lumbar spine and total
hip, respectively. Long-term quality control of the instrument was
assured by daily scan using a standard spine phantom as instructed
by the manufacturer. All scans were performed in the same
machine by the same operator and were analyzed by a physician
blinded to the group the participant belonged. Consistent with the
recommendations from WHO [23] and from the International
Society of Clinical Densitometry [16], men 50 years and older
were classified according to T-score as normal bone density (T-
score above – 1.0 SD), osteopenia (21.0, T-score ,22.5) or
osteoporosis (T-score below – 2.5 SD). Z-score was used to classify
younger men (less than 50 years old) as within the expected range
for age (Z-score above – 2.0) or below the expected range for age
and sex (Z-score below – 2.0). For comparison purposes, BMD
measurements in both groups were adjusted for age and body
weight.
Laboratory tests
Blood was drawn in the morning after an overnight fasting.
Routine tests included total serum calcium, phosphate, and
creatinine and total alkaline phosphatase using standard methods.
Intact parathyroid hormone (iPTH) (Nichols AdvantageH Chemi-
luminescence Intact Immunoassay; interassay coefficient of
variation of 7%; normal range 10–65 pg/mL), 25-hydroxy
vitamin D (25OHD) (radioimmunoassay technique, DiaSorin,
Stillwater, MN, USA; intra- and inter-assay coefficients of
variation were 9.5% and 15.2%, respectively) and type I collagen
C-telopeptide (CTx) serum concentrations (Elecsys 2010 automat-
ed analyzer, Roche; interassay coefficient of variation of 6%;
normal range 0.081–0.850 ng/mL) were also determined.
HCV viral load and genotype, liver biopsy classification and
serum albumin were obtained from an extensive review of the
patients’ charts.
Vertebral fracture assessment
Radiographic lateral and posterior-anterior images of thoracic
and lumbar spine were taken according to standard protocols
aiming to evaluate asymptomatic vertebral fractures. Thoracic
films were centered at T8 and lumbar films at L3. Focus film
distance was 1.5 m. A semi-quantitative method [24] was used to
determine the prevalence of vertebral deformities. Only grades II
and III were considered as vertebral fractures. Intra and inter-
observer coefficients of variation and kappa indexes for the
method in our unit are 4.8% (concordance 95.2%) and 6.3%
(concordance 93.7%) and 0.84 (95%CI 0.78–0.92) and 0.82
(95%CI 0.75–0.9), respectively [21].
Statistical analysis
Results were expressed as mean 6 standard deviation. Chi-
squared tests were used to evaluate the prevalence of osteoporosis,
osteopenia, and low BMD as well as the vitamin D status between
CHC men and their healthy controls. We compared the BMD,
anthropometric variables, frequency of risk factors for osteoporosis
and laboratorial tests between CHC patients and healthy controls
using Student’s t-tests. Two-way ANOVA analyzes were used to
adjust vitamin D concentrations according to the season of the
year. Pearson’s and Spearman’s coefficient of correlation were
used to estimate association between clinical variables and BMD
measurements with the prevalence of low bone mass and
osteoporosis in CHC patients. Potential risk factors for low bone
mass and osteoporosis were analyzed by backward stepwise
regression analysis using variables identified in correlation
analyzes. SPSS statistical package for Windows (version 15.0)
was used to analyze the data. Significance level was set as p,0.05.
Results
Relevant demographic and clinical characteristics for both
CHC patients and healthy men are shown in Table 1. CHC
patients had lower physical activity and reported prolonged
immobilization more often than healthy men (p,0.05). In spite of
their similar weight and height, CHC patients had significantly
higher BMI values as compared to the healthy controls (p = 0.04).
Spine and femoral neck BMD did not differ significantly
between HCV patients and healthy men, as demonstrated in
Table 2. On the other hand, total femur and trochanter BMD
values were significantly lower in CHC men as compared to
healthy controls, even after adjustments for body weight (p,0.05).
Non-Cirrhotic Hepatitis C Leads to Low Bone Mass
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For subjects younger than 50 years old, BMD measurements
below the expected range for age and sex (Z-score below – 2.0)
were found in 1 (at the femur) out of 41 CHC patients (3%) and 2
(one at the femur, one at the lumbar spine) out of 40 controls (5%).
Again, no statistically significant difference was observed between
groups. For men 50 years old or more, osteoporosis was detected
in 36% of the CHC patients (two patients at both femur and
lumbar spine, three patients at the femur and two other patients at
the lumbar spine) and in only 4% of the healthy men (2 at the
femur and two others at the lumbar spine). Osteopenia was
observed in 32% of both groups (three patients at the femur and
three others at the lumbar spine; five healthy controls had
osteopenia at the lumbar spine and one of them had osteopenia at
the femur). BMD classified as normal was found in 32% of the
CHC patients and in 64% of the controls (p=0.01).
Serum concentrations of biochemical bone markers were in the
normal range for both CHC patients and controls as shown in
Table 3. Total calcium, phosphate, alkaline phosphatase, iPTH,
CTx and vitamin D did not differ significantly between HCV
patients and controls. The mean serum albumin was also within
the normal limits in CHC patients (4.2560.4 mg/dL).
Using previously published criteria [25], 25OHD status was
classified in patients and controls as follows: sufficiency (above
30 ng/mL), insufficiency (11–29 ng/mL) and deficiency (below
10 ng/mL). After adjustments for the season of the year, no
statistically significant difference was observed between the groups
in terms of 25OHD status (Table 4).
Chi-squared test and linear backward stepwise regression
analyses were performed to investigate potential determinants
for low BMD in our sample. BMD measurements at all skeletal
sites did not correlate with lifetime tobacco exposure (pack-years of
smoking), alcohol consumption (drinks/week), physical activity
[26], prolonged immobilization, time since diagnosis and contam-
ination, viral load and genotype, degree of liver inflammation and
fibrosis at the biopsy in CHC patients. Although CTx serum
concentrations correlated negatively with lumbar spine BMD
(r =20.21; p=0.04), no other significant correlation was found
between BMD measurements and other biochemical markers.
Multivariate analyzes performed did not allow to identify any
parameter significantly associated with low BMD measurements in
CHC patients.
Morphometric vertebral fractures were observed in three
healthy men and one CHC patient. The CHC patient was a 57
years-old man with history of current smoking (40 pack-years) and
alcohol use (10 drinks/week). BMD measurements, bone markers
and vitamin D status were in the normal range for this patient.
Due to the few number of vertebral fractures in the sample,
correlation and regression analyzes were not feasible and so the
study was not able to evaluate whether vertebral fractures are
associated with HCV infection.
Table 1. Demographic data and clinical characteristics of chronic hepatitis C (CHC) men and healthy controls.
CHC (N=60) Controls (N=59) p*
Age (years) 41.50610.90 41.70610.80 0.92
Weight (kg) 77.50615.70 79.60611.70 0.07
Body mass index (kg/m2) 26.1064.60 26.8063.00 0.04
Smoking, n (%) 18.00 (30%) 18.00 (31%) 0.95
Lifetime tobacco exposure (pack-years) 27.00612 28.00611 0.71
Drinking habits, n (%) 27.00 (45%) 39.00 (66%) 0.07
Alcohol intake (drinks/week) 3.8063.40 4.1063.10 0.53
Physical activity**, n (%) 14.00 (23%) 24.00 (40%) 0.04
Previous prolonged immobilization, n (%) 14.00 (23%) 2.00 (3%) 0.001
Family history of osteoporosis, n (%) 11.00 (18%) 15.00 (25%) 0.34
Family history of femur fracture, n (%) 5.00 (8%) 9.00 (15%) 0.24
**Physical activity at least 3 times/week, for 30 minutes;
*Student t-test
doi:10.1371/journal.pone.0081652.t001
Table 2. Bone mass measurements in CHC patients and
healthy controls.
Bone mineral density
(g/cm2) CHC (N=60) Controls (N=59) p*
Spine (L1–L4) 1.16860.15 1.16560.15 0.96
Femoral neck 1.02960.17 1.06160.17 0.49
Trochanter 0.87060.13 0.92360.13 0.03
Total Hip 1.05160.15 1.11160.15 0.04
*Student t-test
doi:10.1371/journal.pone.0081652.t002
Table 3. Biochemical bone markers and laboratory tests of
bone and mineral metabolism in CHC men and healthy
controls.
CHC (N=60)
Controls
(N=59) p*
Total calcium (mg/dL) 9.0960.40 9.0860.30 0.76
Phosphate (mg/dL) 3.1160.40 3.0460.30 0.32
Creatinine (mg/dL) 0.8960.10 0.9160.10 0.41
Alkaline phosphatase (UI/dL) 85.50668.02 72.70619.20 0.44
Intact PTH (pg/mL) 56.20622.04 51.90623.02 0.19
CTx (ng/mL) 0.4060.33 0.4260.15 0.07
25 OHD (ng/mL) 30.60610.02 28.5068.10 0.16
*Student t-test
doi:10.1371/journal.pone.0081652.t003
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Discussion
Our results demonstrated that non-cirrhotic untreated CHC
men have lower total hip and trochanter BMD when compared to
healthy men. Only a few studies had evaluated BMD measure-
ments in non-cirrhotic CHC patients and their results are
conflicting due to methodological questions [13–15]. In our
present sample we were able to demonstrate that HCV infection
affects BMD at the proximal femur independently of liver
function, current cirrhosis or anti-viral medication.
In spite of the lower BMD values in CHC patients when
compared to healthy men, mean BMD at all skeletal sites were
within normal range. It is interesting to note that both CHC
patients and healthy controls exhibited high prevalence of
overweight and that is well recognized as having a protective
effect on bone density [27–30].
Total hip BMD is highly influenced by trochanteric BMD since
the trochanter occupies the largest area of the proximal femur.
The lower values for total hip BMD observed among CHC
patients may be explained by the significantly lower BMD
measurements at the trochanter in these subjects. In agreement
with this finding, other authors have also observed a significant
decrease in trochanter BMD in CHC patients, regardless of the
liver function [14].
Reduced current physical activity associated with higher
prevalence of prior prolonged immobilization were also observed
among CHC patients as compared to healthy controls and that
may also have influenced our results. Lower mechanical load
could be related to the lower values for trochanteric BMD
observed among CHC patients. Studies with hemiplegic patients
[31] and cosmonauts [32] have demonstrated the association
between reduced weight-bearing activities and lower femur BMD.
The effect is probably due to an increase of the number of
osteoclasts and a decrease in the osteoblast population [33].
Hepatic dysfunction with the intervenient vitamin D deficiency
has been associated with low bone density. A direct correlation has
been reported between the severity of liver fibrosis and low bone
density in non-cirrhotic CHC patients [15]. The issue is however
controversial and in CHC patients without cirrhosis the associa-
tion with low BMD has not been confirmed in all studies.
Hofmann et al [34] reported no correlation between non-cirrhotic
hepatic disease and BMD measurements. They have also found no
association between BMD measurements and disease duration,
viral load and lifetime tobacco exposure. Our data have
demonstrated no significant correlation between BMD measure-
ments and the severity of liver inflammation and fibrosis at the
biopsy, viral load, transmission model, estimated disease duration
or alcohol intake. It is important to note that patients with
alcoholism were excluded from our study.
Our results have also shown that non-cirrhotic CHC patients
present no clinically relevant abnormalities in bone markers and
calciotropic hormones, as previously observed [13–15,34]. Mean
serum 25OHD concentrations were considered sufficient in CHC
patients, corroborating previous findings [14,34]. To our knowl-
edge this is the first study to classify non-cirrhotic CHC patients
according to vitamin D status. No significant difference was
observed in 25OHD status between CHC patients and healthy
controls. That also suggests that liver injury in our patients was not
important, at least in terms of vitamin D synthesis and
hydroxylation.
The number of morphometric vertebral fracture was rather
small in both groups precluding further analyzes. The absence of
vertebral fractures may also result from the normal lumbar BMD
values observed in both CHC patients and healthy controls.
Some limitations of the present study need to be pointed out.
Our cross-sectional design prevented us of establishing a cause-
effect relationship in our results as well as evaluating the long-term
effect of HCV infection on bone metabolism and fracture risk. As
observed earlier, the high prevalence of overweight in our
population might also have influenced our results and could have
positively impacted on BMD measurements in both groups.
Results in women chronically infected with HCV might be
somewhat different from those reported here for men.
This study is the first to evaluate BMD, bone metabolism and
the prevalence of morphometric vertebral fracture in a significant
number of men with CHC, without the classic confounding factors
for low bone density (menopause, cirrhosis and antiviral therapy).
Our results demonstrate that non-cirrhotic untreated CHC
patients are at low risk for osteoporosis and fractures. We have
also observed no significant abnormalities in bone and mineral
metabolism and a vitamin D status similar to that seen for healthy
men.
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